SGS Increases Biosafety Testing Capacity at Glasgow Facility
SGS has just completed an expansion project at its Glasgow facility, meaning it can provide increased biosafety testing for the biologics, drug development, and cell and gene therapy industries.
The project, which began back in March 2021 and was completed in September 2021, saw the footprint of the Glasgow facility increase by 550m2, meaning the facility now totals 3,100m2 in size and has a staff of 130 employees.
Sixteen BSL-2 laboratories have been added to our Glasgow facility. These laboratories contain a range of equipment, including BSL-2 cabinets, ELISA (enzyme-linked immunosorbent assay) technology, cell culture equipment for virus detection and real-time PCR (polymerase chain reaction) testing equipment.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025